This report was first published by Endpoints News. To see the original version, click here
A nimble Santa Cruz, CA-based biotech has corralled a $45 million Series B to prove whether its decade of R&D in the burgeoning macrocycle space is ready for the big time.
The 50-employee company, called Unnatural Products, is a relative veteran of the macrocycle field. It was founded a decade ago based on its CEO and chief scientific officer’s PhD work at UC Santa Cruz.
您已阅读13%（462字），剩余87%（3072字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。